Navigation Links
Research reveals effectiveness of seizure treatments for children with autism
Date:6/2/2011

Physicians will have a better guide for more effectively managing treatment of children experiencing seizures related to autism with the results of a study by researchers at Arizona State University and the University of Texas-Houston.

From 25 to 35 percent of people with autism will eventually experience full-scale seizures. Many others will have seizure-like brain activity, in which there is no obvious effect on muscles but potential effects on brain functioning, such as temporary loss of attention.

Little has been known about which traditional treatments for epileptic seizures and commonly used non-traditional alternative treatments are most effective for treating seizures or epilepsy specifically in children and adults with autism.

The new study provides insight into which treatments are most beneficial in such cases, says James Adams, a professor in the School for Engineering of Matter, Transport and Energy, one the ASU's Ira A. Fulton Schools of Engineering.

Adams conducted the research with Richard E. Frye, a physician specializing in child and behavioral neurology in the Department of Pediatrics at UT-Houston.

The complete study is published in the medical journal BMC Pediatrics, and is available online at http://www.biomedcentral.com/1471-2431/11/37/abstract

Adams says the study "suggests that several non-traditional treatments, such as special diets ketogenic, Atkins, and gluten-free, casein-free diets, in particular are worth further investigation as supportive treatments" for managing the health of people with autism who suffer from seizures.

Adams and Frye surveyed 733 parents whose children with autism experience seizures, epilepsy and/or seizure-like brain activity. They asked parents to rate the effectiveness of 25 traditional and 20 non-traditional medical treatments for seizures.

The survey also assessed the effects and side-effects of those treatments. Overall, antiepileptic drugs were reported by parents to reduce the occurrence and severity of seizures but worsened problems with sleep, communication, behavior, attention and mood.

Non-antiepileptic drugs were perceived to improve other symptoms but did not reduce occurrence of seizures or make them less severe to the same extent as the anti-epileptic drugs.

Four anti-epileptic drugs valproic acid, lamotrigine, levetiracetam and ethosuximide were reported to most often reduce the number or lessen the severity of seizures, and on average have little positive or negative effect on other symptoms of autism.

Certain traditional non-anti-epileptic drug treatments, particularly the ketogenic diet, were perceived to both lessen the number and reduce the severity of seizures and other symptoms.


'/>"/>

Contact: Joe Kullman
joe.kullman@asu.edu
480-965-8122
Arizona State University
Source:Eurekalert

Related biology news :

1. Wistar Institute researcher receives New Innovator award from NIH
2. NC State researchers get to root of parasite genome
3. White Mountain Research Station to host climate change conference
4. Stevens awarded $1M for advanced biofuels research
5. Researchers find animal with ability to survive climate change
6. Researchers find an essential gene for forming ears of corn
7. Researchers note differences between people and animals on calorie restriction
8. Researcher working on destruction of chemical weapons
9. Researchers study acoustic communication in deep-sea fish
10. Researchers discover that growing up too fast may mean dying young in honey bees
11. The Rett Syndrome Research Trust launches operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2016)... "The biometric system market projected to ... system market is in the growth stage and is ... biometric system market is expected to be valued at ... 16.79% between 2016 and 2022. Government initiative in adoption ... rising use of biometric technology in financial institutes and ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... Medical LiveWire Healthcare and Life Sciences Awards as ... caps off an unprecedented year of recognition and growth ... for over 15 years. iMedNet ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ... Banks and Academics) market is to witness a value of ... the highest Compounded Annual Growth Rate (CAGR) of 10.75% is ... analysis period 2014-2020. North America is ... Europe at 9.56% respectively. Report ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 2016 AskLinkerReports.com has published a report ... Amyloglucosidase Industry 2016 Market Research Report. From a basic outline ... overview are all covered in the report. This report projects ... analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... CARDIFF, UK (PRWEB) , ... December 08, 2016 ... ... high precision light to control cells — optogenetics — is key to exciting ... state of the art, spatially patterned light projected via free-space optics stimulates small, ...
(Date:12/8/2016)... 2016 Oxford Gene ... seine Palette an anpassbaren SureSeq™ NGS-Panels mit dem ... das ein schnelles und kostengünstiges Studium der Varianten ... eine Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) ... kleinen Panel und ermöglicht eine individuelle Anpassung durch ...
Breaking Biology Technology: